Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

See original article:
Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Scroll to Top